Potential Sciences uses artificial intelligence trained on computer-generated data to develop new medicines. The UK-based startup plans to skip physical laboratory work entirely. Its goal is to accelerate the drug development process. The founders believe that relying on synthetic data is the key to faster innovation.
The company is backed by the UK government. Developing new drugs is a laborious and slow process. Potential Sciences bets on skipping physical lab work to overcome these traditional bottlenecks. The AI models are trained on synthetic data generated by computers rather than collected from physical experiments.
This approach could significantly reduce the time and cost required to bring new treatments to market. Researchers and investors in the biotech sector should pay close attention to how well these synthetic models perform in real-world scenarios. It is a bold strategy that challenges the long-standing reliance on wet lab experimentation.
